<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489004</url>
  </required_header>
  <id_info>
    <org_study_id>Credit-AF</org_study_id>
    <nct_id>NCT04489004</nct_id>
  </id_info>
  <brief_title>The Chinese Registration Study of Driver Ablation of Persistent Atrial Fibrillation.</brief_title>
  <official_title>Credit-AF: A Randomized Control Study of Driver Ablation Combined With Circumferential Pulmonary Vein Isolation Versus Stepwise Ablation as a Treatment in Patients With Persistent Atrial Fibrillation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-center, randomized parallel control clinical trial, to&#xD;
      demonstrate the role of driver mechanism in maintenance substrate of persistent atrial&#xD;
      fibrillation, and evaluate the clinical outcomes of driver mapping and ablation strategy in&#xD;
      patients with persistent atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multi-center, randomized parallel control clinical trial. Patients&#xD;
      with persistent atrial fibrillation are 1:1 randomized into the experimental group (driver&#xD;
      ablation+ circumferential pulmonary vein isolation) or the control group (stepwise ablation).&#xD;
      Postoperative atrial fibrillation recurrence rate and other indicators are analyzed to&#xD;
      demonstrate the role of driver mechanism in maintenance substrate of persistent atrial&#xD;
      fibrillation and evaluate the clinical outcomes of driver mapping and ablation strategy in&#xD;
      patients with persistent atrial fibrillation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative atrial fibrillation (AF) recurrence rate</measure>
    <time_frame>up to 24 months after enrollment</time_frame>
    <description>AF recurrence is defined as presence of documented AF episodes of 30 seconds or longer duration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural AF termination rate</measure>
    <time_frame>Before the end of procedure.</time_frame>
    <description>AF termination is defined as conversion to sinus rhythm or a stable atrial flutter (AFL)/atrial tachycardia (AT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative atrial flutter (AFL) or atrial tachycardia (AT) rate</measure>
    <time_frame>up to 24 months after enrollment</time_frame>
    <description>Occurrence of AFL/AT is defined as presence of documented AFL/AT episodes of 30 seconds or longer duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications</measure>
    <time_frame>up to 2 weeks after enrollment</time_frame>
    <description>Complications include: death, atrioesophageal fistula, cardiac tamponade/perforation, myocardial infarction, stroke/cerebrovascular accident, thromboembolism, transient ischemic attack (TIA), diaphragmatic paralysis, pneumothorax, heart block, pulmonary vein stenosis, pulmonary edema, pericarditis, and major vascular access complication or bleeding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1298</enrollment>
  <condition>Atrial Fibrillation, Persistent</condition>
  <arm_group>
    <arm_group_label>Driver ablation+CPVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Driver ablation plus CPVI (circumferential pulmonary vein isolation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stepwise ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stepwise ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Driver ablation+CPVI</intervention_name>
    <description>Patients receive driver ablation and CPVI (circumferential pulmonary vein isolation).</description>
    <arm_group_label>Driver ablation+CPVI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stepwise ablation</intervention_name>
    <description>Patients receive stepwise ablation.</description>
    <arm_group_label>Stepwise ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 to 80 years old;&#xD;
&#xD;
          2. Persistent AF;&#xD;
&#xD;
          3. nonresponse or intolerance to â‰¥1 antiarrhythmic drug. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With uncontrolled congestive heart failure;&#xD;
&#xD;
          2. Having significant valvular disease and/or prosthetic heart valve(s);&#xD;
&#xD;
          3. With myocardial infarction or stroke within 6 months of screening;&#xD;
&#xD;
          4. With Significant congenital heart disease;&#xD;
&#xD;
          5. Ejection fraction was &lt;40% measured by echocardiography;&#xD;
&#xD;
          6. Allergic to contrast media;&#xD;
&#xD;
          7. Contraindication to anticoagulation medications;&#xD;
&#xD;
          8. Severe pulmonary disease e.g. restrictive pulmonary disease, chronic obstructive&#xD;
             disease (COPD);&#xD;
&#xD;
          9. Left atrial (LA) thrombus measured by pre-procedure transesophageal echocardiography;&#xD;
&#xD;
         10. Having any contraindication to right or left sided heart catheterization;&#xD;
&#xD;
         11. Previous atrial fibrillation ablation;&#xD;
&#xD;
         12. Presence of an implanted cardioverter-defibrillator;&#xD;
&#xD;
         13. Any cardiac surgery within the past 2 months;&#xD;
&#xD;
         14. Poor general health;&#xD;
&#xD;
         15. Life expectancy less than 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mu Qin, M.D.</last_name>
    <phone>+8613052320103</phone>
    <email>qinmuae@163.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Xu Liu</investigator_full_name>
    <investigator_title>Professor, deputy director of cardiology department of Shanghai Chest Hospital</investigator_title>
  </responsible_party>
  <keyword>Persistent Atrial Fibrillation</keyword>
  <keyword>Driver ablation</keyword>
  <keyword>Stepwise ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

